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ABSTRACT. At present, the only proven way to treat glaucoma is to lower intraocular pressure (IOP). Osmotic 
agents constitute an important class of ocular hypotensive agents. These medications are used for the rapid reduction of 
IOP, typically in emergency situations, in which IOP is severely elevated and there is a high risk of permanent and irre-
versible damage of the optic nerve. This paper summarizes the current state of knowledge on the mechanism of action 
of osmotic agents and their effect on IOP in dogs. Moreover, it discusses the possible undesirable side effects of these 
medications and presents the current ideas about their role and status in the medical management of canine glaucoma.
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INTRODUCTION
Glaucoma is a heterogeneous group of disorders usually associated with elevated intraocular 
pressure (IOP) leading to optic nerve damage, 
retinal ganglion cell death, and permanent vision 
loss. It is one of the most common causes of 
irreversible blindness in dogs (Miller, 2013). The 
pathophysiological process of glaucomatous optic 
neuropathy is not fully understood, but it is likely 
to be a multifactorial result. An increase in IOP 
is the principal risk factor for glaucoma, and the 
primary goal of treatment is to reduce IOP to values 
that will halt the degeneration of retinal ganglion 
cells (Smith et al., 2010). There are two principal 
ways to reduce IOP medically: by lowering aqueous 
humour (AH) production and by increasing AH 
outflow, and these effects can be achieved via a 
number of different mechanisms of action. Although 
some ocular hypotensive drugs are likely to lower 
IOP by affecting both AH formation and outflow, 
based on the dominant way of action they are 
divided into following groups: (a) those that reduce 
AH production (i.e. carbonic anhydrase inhibitors 
[CAIs], β-adrenergic antagonists, and selective 
α2-adrenergic agonists), and (b) those that increase 
AH outflow (i.e. nonselective adrenergic agonists, 
parasympathomimetics, and prostaglandin F2α 
analogues). The third group of medications employed 
in the treatment of glaucoma are osmotic drugs; 
although these agents also enhance the outflow of 
AH and most probably reduce AH formation, they 
are traditionally distinguished as a separate class. 
The present paper constitutes the fifth and final 
paper in a series devoted to the pharmacological 
characterization of ocular hypotensive drugs in 
the context of their application for the therapy of 
glaucoma in small animals (Maślanka, 2014a, 2014b; 
Maślanka, 2015a, 2015b).
HISTORY & CLASSIFICATION
The earliest reports on use of this type of 
substances in therapy of glaucoma date back to 
1904, when Cantonnet published results of a study 
on the effect of oral administration of lactose and 
sodium chloride on IOP of patients suffering from 
this disease. Ten years later, Hertel (1914) reported 
that intravenous administration of urea caused a 
decrease in IOP in rabbits. In 1958 Javid verified the 
IOP-lowering effect of urea, whereas in the 1960s it 
was discovered that the same effect is produced by 
mannitol (Weiss et al., 1962), glycerol (Virno et al., 
1963) and isosorbide (Becker et al., 1967). Osmotic 
agents can be subdivided into two groups based on 
the route of administration:
•  intravenously administered agents:
mannitol and urea
•  orally administered agents:
glycerol and isosorbide
MECHANISM OF ACTION
With respect to the location of a target site, two 
types of mechanisms responsible for the IOP-
lowering effect of osmotic agents are distinguished 
(Serle et al., 2003; Stamper et al., 2009; Toris, 2010):
Direct mechanism: Osmotic agents increase 
the osmolality of the intravascular fluid compared 
with the extravascular fluid. These agents penetrate 
very slowly into the avascular vitreous, since the 
blood-ocular barriers (i.e. blood-aqueous and blood-
vitreous barriers) restrict their penetration into the 
eye, creating an osmotic gradient: extraocular fluids 
are hypertonic to intraocular fluids (i.e. AH and 
vitreous) (Serle et al., 2003). This osmotic gradient 
draws water from the intraocular space into the 
circulation via the blood vessels of the retina and 
uveal tract (Duncan et al., 1969, 1970; Stamper et 
al., 2009). The main effect is the dehydration of the 
vitreous body, causing a reduction of its volume 
(Robbins and Galin, 1969; Duncan et al., 1970). It 
has been demonstrated that the weight of the rabbit 
vitreous body was reduced by 2.7%, 3.7% and 3.9% 
after administration of glycerol, urea and mannitol, 
respectively (Robbins and Galin, 1969). It is held 
that reduction of the volume of the vitreous body is 
the primary mechanism responsible for the ocular 
hypotensive effect of osmotic agents (Duncan et al., 
1969, 1970; Serle et al., 2003). It is assumed that 
shrinkage of the vitreous body displaces the iris-lens 
diaphragm posteriorly and subsequently opens the 
iridocorneal angle, which increases aqueous outflow 
facility (Craig, 1994; Willis, 2004; Regnier, 2007). 
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This claim is also supported by reports indicating that 
the use of mannitol leads to the enlargement of the 
anterior chamber depth (Weiss et al., 1963; O’Keeffe 
and Nabil, 1983). It is also proposed that the fluid 
movement described above, inhibits the ultrafiltration 
process that contributes to AH formation (Willis, 
2004; Regnier, 2007). This suggests that the reduction 
in AH production could represent an additional 
mechanism involved in the IOP-lowering action of 
osmotic drugs. 
Indirect mechanism: Osmotic agents reduce AH 
production via a central nervous system pathway 
involving osmoreceptors in the hypothalmus 
(Stamper et al., 2009). This theory is supported by 
several evidences obtained from studies performed 
in animal models and human patients. It was 
demonstrated that small doses of hyperosmotic agents 
that do not increase plasma osmolality, reduced IOP 
(Podos et al., 1971). Mauger et al. (2000) showed 
an ocular hypotensive effect of mannitol without 
reducing vitreous volume using a relatively low 
dose of mannitol. Krupin et al. (1973) found that 
administration of hypoosmotic agents into the third 
ventricle resulted in an elevation of IOP, while 
delivery of hyperosmotic agents lowered IOP. 
Moreover, the unilateral optic nerve transection in 
experimental animals reduced the IOP response to 
hypoosmotic and hyperosmotic agents, as it was 
shown in these studies along with some earlier 
investigations (Riise and Simonsen, 1969) This 
was the basis for formulating a hypothesis that a 
hypothalamic center with osmoreceptors participated 
in IOP regulations (most probably via its effect 
on AH formation) by efferent fibers in the optic 
nerve. However, subsequent studies did not reveal 
that the optic nerve transection affected the ocular 
response to the hypotensive action of osmotic agents 
(Serafano and Brubaker, 1978; Lam et al., 1980). 
Thus, these results do not support the hypothesis 
that the optic nerve carries fibers which are part of 
the control system for IOP (Serafano and Brubaker, 
1978). Nevertheless, in light of the above results, it is 
probable that the hypothalamic center mediates part 
of IOP responses to osmotic agents; it is questionable 
whether this effect is mediated by efferent fibers in 
the optic nerve.
EFFECT ON IOP
The literature revealed only four studies on the 
effect of osmotic agents on IOP in dogs (Gilroy, 
1986; Lorimer et al 1989; Volopich et al., 2006; 
Wasserman et al., 2013). Gilroy (1986) did not find 
any effect of a mannitol infusion (0.25 g/kg) on the 
IOP in dogs. The dose applied in this experiment was 
very low, although it is known that rates of mannitol 
in this order can lower IOP in human patients 
(Marshall et al., 1978). Gilroy (1986) assumed that 
the dosage of mannitol that was adequate to treat 
elevated IOP in humans did not affect IOP in normal 
dogs. Volopich et al. (2006) evaluated the effect of 
higher dose of mannitol (1 g/kg) and hypertonic 
hydroxyethyl starch (HES; 1.2 g/kg BaCl; 0.96 g/
kg HES) on IOP in healthy normotensive dogs. A 
significant decrease in IOP from baseline value was 
found at 15, 30, 45, and 60 min after the start of 
mannitol administration (mean amplitude in IOP 
decrease 3.21 mmHg) and at 15 and 30 min in dogs 
treated with HES (mean amplitude in IOP decrease 
2.43 mmHg). The authors of this study (Volopich 
et al., 2006) concluded that hypertonic HES is 
comparable to mannitol (at doses applied in the 
experiment) in lowering IOP in healthy normotensive 
dogs. But this effect lasted half an hour longer after 
mannitol. Moreover, they evaluated the potential 
IOP-lowering effect of hypertonic HES in six dogs 
with primary glaucoma. In 6/7 eyes with primary 
glaucoma, hypertonic HES decreased IOP (Volopich 
et al., 2006). In another study (Lorimer et al., 1989), 
the effect of mannitol (1.5 g/kg) or oral glycerol (1.4 
and 2.0 g/kg) on IOP was investigated in normal 
dogs. Mean IOPs were significantly decreased from 
baseline values from 0.5 through 5.5 hr following 
mannitol administration with a mean maximum 
depression of 8.7 mmHg, which occurred 1.5 hr 
after administration. Administration of glycerin led 
to a significant IOP-lowering effect (with a mean 
maximal decrease of 5.4 mmHg), occuring within 1 
hr and lasting 10 hr. Based on these results, it was 
concluded that both mannitol (1.5 g/kg) and glycerol 
(1.4 g/kg) are effective for decreasing IOP in normal 
dogs. This conclusion (regarding glycerol) does not 
agree with the recently published results of a study on 
the effect of oral isosorbide (1.5 g/kg) and glycerol 
(1.5 g/kg) on IOP in normal dogs (Wasserman et al., 
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2013). The maximal reduction in IOP was 17% by 1 
hr and 13.5% by 30 min after glycerol and isosorbide 
administration, respectively. However, the overall 
changes in IOP were not significant when compared 
to the controls. Therefore, the authors claim that 
neither glycerol nor isosorbide significantly affected 
IOP when compared to the control (Wasserman 
et al., 2013). Still they consider that it is possible 
that the trend of decreased IOP would have 
approached significance had this evaluation included 
glaucomatous subjects. This is supported by previous 
studies, which determined that both isosorbide 
(Wisznia et al., 1970; Kulshrestha and Mittal, 1972) 
and glycerol (Drance, 1964; Consul and Kulshrestha, 
1965) are significantly more effective at lowering IOP 
in glaucomatous versus normotensive human patients 
(Wasserman et al., 2013).
CLINICAL USE
Osmotic drugs are used for the rapid reduction of 
intraocular pressure, typically in emergency situations 
in which IOP is severely elevated and there is a high 
risk of permanent and irreversible damage of the 
optic nerve (Toris, 2010). These medications are 
used only for short-term control of IOP, because 
their serious side effects and short duration of 
action, preclude their use for long-term glaucoma 
therapy. The most common osmotic medications 
used to treat glaucoma in dogs are mannitol and 
glycerol (Willis, 2004). Rapid reduction of IOP is 
usually achieved with mannitol rather than glycerol 
(Regnier, 2007). Oral glycerol (1 to 2 ml/kg) is an 
alternative to mannitol (Miller, 2013). The main 
advantage of glycerol is the low cost and the route 
of oral administration. Osmotic agents are used 
in emergency treatment of acute glaucoma an and 
before surgical procedures for glaucoma (Gelatt et al., 
2007). These drugs are primarily used to lower IOP 
in acute primary closed-angle glaucoma (PCAG). 
Because the response of the eye to miotics does 
not occur when IOP is greater than approximately 
50 mmHg [the pupillary sphincter muscle is 
ischemic and unresponsive to miotics when the 
IOP is above 40-50 mm Hg (Anderson and Davis, 
1975)], reduction of IOP by these agents is essential 
(Gelatt et al., 2007). Mannitol may be employed 
both before and during surgical lens procedures 
(i.e. cataract surgery, removal of a luxated lens), 
because shrinkage of the vitreous body decreases the 
incidence and severity of vitreous prolapse (Regnier, 
2007). With pupillary-block glaucoma in the dog, 
in which lens, vitreous, or both obstruct the pupil, 
administration of osmotic agents is essential (Gelatt 
et al., 2007). The integrity of the blood-aqueous 
barrier is important for these medications to be 
effective; IOP-lowering effect of osmotic agents may 
be reduced in patients with intraocular inflammation 
(Dugan et al., 1989).
According to treatment algorithms for various types 
of glaucoma recommended by Miller (2013): 
• mannitol (1.0 to 1.5 g/kg) in combination 
with systemic CAIs and pilocarpine should 
be considered as a second-line or alternative 
option for emergency therapy of dogs with 
acute PCAG, when treatment with latanoprost 
is ineffective or its administration is impossible, 
respectively. The author (Miller, 2013) adds 
that because mannitol can be quite toxic, its 
application should be limited to eyes with the 
potential for vision.
• mannitol (1.0 to 1.5 g/kg) in combination 
with CAIs should be considered as a second 
line treatment for emergency therapy of lens 
luxation-associated glaucoma, when treatment 
with mydriatic agents and steroid anti-
inflammatory drugs is ineffective.
If IOP remains elevated after a single injection of 
mannitol, the 1.0 g/kg dose may be repeated in 4 hr 
if necessary, but long-term use should be avoided 
(Miller, 2013).
SIDE EFFECTS
The major potential toxicity of i.v. administration 
of osmotic agents is related to their effect on the 
volume and distribution of body fluids (Regnier, 
2007). These medications cause relative dehydration 
of the extracellular spaces and subsequently fluid 
shift into the intravascular space, which can lead to 
overload of the cardiovascular system, effect that is 
particularly evident in the case of mannitol (Borges 
et al., 1982; Dugan et al., 1989). These effects 
are responsible for many of the adverse effects of 
osmotic agents. Whereas healthy individuals can 
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tolerate these changes, the increased intravascular 
volume can induce acute cardiac failure and 
pulmonary edema in patients with chronic congestive 
heart failure (Borges et al., 1982; Dugan et al., 1989; 
Regnier, 2007). Atkins et al. (1973) investigated the 
cardiovascular response to 25% mannitol (in doses 
of 1.25 ml/kg and 5 ml/kg) in dogs. After the smaller 
dose, stroke volume and left ventricular maximal dp/
dt rose significantly, while no change occurred in 
left ventricular end-diastolic pressure. At the larger 
dose, further increases in stroke volume and max 
dp/dt were accompanied by significant elevations in 
heart rate, mean aortic pressure, and left ventricular 
end-diastolic pressure (Atkins et al., 1973). Brock 
and Thurmon (1979) reported cases of deaths of dogs 
and cats due to pulmonary edema in anesthetized 
patients given mannitol during ophthalmic surgery. 
In a later study, Brock et al. (1985) demonstrated 
that the administration of mannitol in a dose of 2.2 
g/kg to healthy anesthetized dogs was related to 
a risk of causing pulmonary edema. Nausea and 
vomiting are the most common adverse effects of 
osmotic agents, especially when given orally. Oral 
administration of glycerol (1.4 and 2.0 g/kg) in dogs 
was found to cause vomiting in some animals. The 
incidence of vomiting appeared to be dose related 
(Lorimer et al., 1989). Osmotic agents can increase 
diuresis. This results from the increased intravascular 
volume, as well as the urinary excretion of the agents 
themselves (Serle et al., 2003). It was demonstrated 
that in healthy anesthetized dogs, mannitol (2.2 g/kg) 
caused polyuria, serum hyperosmolarity, decreased 
urine specific gravity, and decreased urine osmolality 
(Brock et al., 1985). The use of mannitol to lower 
IOP is only recommended in patients with normal 
renal function (Willis, 2004). In high concentrations, 
mannitol decreases renal blood flow and glomerular 
filtration rate, which may negatively affect an already 
compromised kidney (Willis, 2004). When used in 
patients with compromised renal function, osmotic 
agents may lead to hyponatremia and hypokalemia. 
The resulting imbalance in electrolytes can lead to 
lethargy, seizures, and coma (Serle et al., 2003). 
Cerebral dehydration with resulting confusion and 
disorientation is more common with intravenously 
administered osmotic agents, due to the rapid 
onset of their effects (Serle et al., 2003). A life-
threatening complication caused by these drugs in 
human patients, is subdural hematoma. This is due 
to the shrinkage of the cerebral cortex, that stretches 
and ruptures aqueous veins between the sagittal 
sinus and the brain surface (Stamper et al., 2009). 
Many of the serious side effects of osmotic agents 
are dose related, therefore in human medicine it 
is recommended that patients should receive the 
minimum dose necessary to reduce IOP to the desired 
level (Stamper et al., 2009).
CONCLUDING REMARKS
Two main mechanisms of action have been pro-
posed for osmotic agents. Firstly, their IOP-
lowering effect can be attributed to the dehy-
dration of the vitreous body, which allows 
the lens and iris to move posteriorly, opening 
the iridocorneal angle and, secondly, to the reduc-
tion of AH production via a central nervous system 
pathway involving osmoreceptors in the hypothal-
mus. The most common osmotic medication used 
to treat glaucoma in dogs is mannitol. Osmotic 
drugs are used for the rapid reduction of intraocular 
pressure, typically in emergency situations in which 
IOP is severely elevated and there is a high risk of 
permanent and irreversible damage of the optic nerve. 
These drugs are primarily used to lower IOP in acute 
PCAG. Moreover, mannitol may be employed both 
before and during surgical procedures on the lens, 
because shrinkage of the vitreous body decreases the 
incidence and severity of vitreous prolapse. Because of 
their serious side effects and short duration of action, 
osmotic agents are not used for long-term therapy of 
glaucoma, but only for short-term control of IOP. 
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